CSI-Dx® accurately detects the RNA of tick-borne pathogens in patient urine within 24-48 hours of laboratory receipt. CSI-Dx® can simultaneously identify multiple tick-borne pathogens in a single specimen, the supporting analysis tool RAPID-Dx™ can report on the presence of medically important genes, such those responsible for antibiotic resistance.
Primary Application Area: Healthcare & Medical Devices
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 5
Vetted Programs/Awards: IPart is Pennsylvania’s premiere Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR) and federal funding assistance program. CSI received a microvoucher award to support the development of an NSF SBIR Phase I proposal.
Organization Type: Early-stage Startup (Seed)
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: CSI® received its initial infusion of operating capital through a $3M convertible debenture, comprised of investors with decades of experience in innovative technologies, medicine, and federal service